Journal of Urology publishes outperformance of Cxbladder

THE JOURNAL OF UROLOGY PUBLISHES OUTPERFORMANCE OF CXBLADDER IN USA COVID19 SETTING The American Urological Association's (AUA) Journal of Urology has published the real world lookback highlighting the clinical utility of Cxbladder being used in the Covid setting for managing patients outside the clinic. The lookback study concluded that the use by physicians of Cxbladder Monitor and Pacific Edge's Patient-In-Home Sampling System reduced the number of cystoscopies required and was feasible and safe for patients being monitored for urothelial cancer during the Covid-19 pandemic. In addition, the study concluded that Cxbladder could be used to further stratify low risk patients for decreased surveillance during the pandemic and beyond. The evaluation and lookback was performed by the University of California San Francisco (UCSF) on a cohort of 52 patients who were being monitored for urothelial cancer as part of their standard of care. Cxbladder Monitor correctly identified those at high risk who immediately underwent cystoscopy. Those patients with low Cxbladder Monitor scores were deemed to be low risk and their cystoscopies were deferred to their next scheduled surveillance visit. The follow-up surveillance cystoscopy for these patients, showed no suspicious tumors and no positive cytology was detected. Cxbladder Monitor missed no tumors and among those detected, a number were high impact tumors. CEO of Pacific Edge, David Darling, said: "This latest published evidence provides a real-world insight into the effectiveness of Cxbladder in helping manage patients who can't come in to the clinic. It is great to see our Patient In-Home Sampling System (PIHSS) being used with such great effect and such compelling results. "The COVID-19 pandemic has brought unprecedented changes to the provision of urologic care in order to minimise risks of transmission. Advances in telemedicine look to be providing a new paradigm for healthcare and Cxbladder and our patient in home sample system are well positioned to continue as an integral part in the detection and management of patients with urothelial cancer." The clinical paper was authored by Carrisa Chu, Kevin Li, Maxwell Meng and Sima Porten and published in the September 2021 issue of the Journal of Urology: PD63-12:USE OF CXBLADDER MONITOR DURING THE COVID-19 PANDEMIC TO REDUCE THE FREQUENCY OF SURVEILLANCE CYSTOSCOPY ENDS For more information contact: David Darling, Chief Executive Officer, Pacific Edge Ltd, P: +64 (3) 479 5800 For media assistance, please contact: Jackie Ellis, P: +64 27 246 2505 E: jackie@ellisandco.co.nz End CA:00377504 For:PEB Type:GENERAL Time:2021-08-18 14:45:55